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Isotopic labelingAs Medicinal Chemists are responsible for the synthesis and optimization of compounds, they often pro-
vide intermediates for use by isotope chemistry. Nevertheless, there is generally an incomplete under-
standing of the critical factors involved in the labeling of compounds. The remit of an Isotope
Chemistry group varies from company to company, but often includes the synthesis of compounds
labeled with radioisotopes, especially H-3 and C-14 and occasionally I-125, and stable isotopes, especially
H-2, C-13, and N-15. Often the remit will also include the synthesis of drug metabolites. The methods
used to prepare radiolabeled compounds by Isotope Chemists have been reviewed relatively recently.
However, the organization and utilization of Isotope Chemistry has not been discussed recently and will
be reviewed herein.
 2014 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Isotope Chemistry (IC) is a specialty function found in many
large pharmaceutical companies. While the remit of IC can vary
from company to company, the principal deliverable is to provide
labeled compounds to the business, mostly for use by drug metab-
olism and pharmacokinetics (DMPK) groups for metabolism based
studies. These deliveries consist primarily of H-3, C-14, and stable
isotope labeled compounds, but may also encompass I-125 and S-
35 as well as unlabeled compounds including metabolites and PET
precursors.1,2
Tritium labeled compounds are used by DMPK to gather early
metabolism data, to assess covalent binding of reactive metabolites
(which is a key component of AstraZeneca’s safety strategy),3 for
transporter efﬂux and uptake studies, and can also be used for
quantitative whole body autoradiography (QWBA).4 Tritium
labeled compounds have many additional applications in biosci-
ence, including receptor binding, autoradiography, and receptor
occupancy studies. They are generally more easily and rapidly syn-
thesized than C-14 labeled compounds but have a far greater
potential for the loss of the label by chemical and biological pro-
cesses. Tritium labeled compounds have a modest speciﬁc activity
which makes them well suited for use with many receptor binding
assays, while simultaneously obviating the need for a decay correc-
tion when used in metabolism studies.
As a project approaches Phase III development, IC provides C-14
labeled material for use in QWBA and mass balance studies, and
ultimately C-14 labeled material for use in human absorption,distribution, metabolism, and excretion, (hADME) studies, which
is prepared according to current good manufacturing practices
(cGMP).4,5 If an absolute bioavailability study is to be run, it is often
conducted at the same time.5 During Phase III and beyond, C-14
labeled material is required for environmental fate studies.6
I-125 and S-35 are typically used only as radioligands.7,8 Both S-
35 and I-125 labeled compounds can be produced in high speciﬁc
activity which makes them ideal for low mass uses such as recep-
tor binding assays. Few drug targets contain iodine and sulfur
atoms and so the radioligands containing them must often be spe-
ciﬁcally designed for that purpose. There are few methods which
incorporate radiolabeled sulfur or iodine into molecules which fur-
ther limits the application of these radioisotopes.8 The use of I-125
labeled peptides is often employed for receptor binding studies.
Two key but often overlooked deliveries from IC are radiochem-
ical purity analyses and re-puriﬁcations. Radioactive compounds,
by their very nature, are unstable and the low levels of detection
of radioactivity often impose higher purity criteria upon radioac-
tive compounds than upon medicinal chemistry compounds. At
times, the rate of decomposition can be high enough to preclude
re-isolation of pure compound, but this is atypical. If the radiola-
beled compound is used rapidly (within 2 weeks for tritium and
two months for C-14), then the purity can generally be assured.
However, if material is to be used for further studies, or a study
is delayed, purity checks and re-puriﬁcations are often required.
Stable isotope labeled (SIL) compounds are those labeled with
nonradioactive isotopes such as C-13, H-2, O-18, and N-15. These
compounds are primarily employed as internal standards for bio-
assays, but can also be used for mechanistic investigations.9 In
168 C. S. Elmore, R. A. Bragg / Bioorg. Med. Chem. Lett. 25 (2015) 167–171some cases, SIL compounds have been investigated as drug candi-
dates in an effort to slow metabolism in certain regions of the mol-
ecule10 and they are occasionally used to assess the bioavailability
of compounds in Phase III.11
In addition to these core deliveries, IC also provides labeled
material for an increasing array of collaboration partners; allowing
access to IC expertise and material that would otherwise be pro-
hibitively expensive. For example, AstraZeneca IC has supported
the Mechanism-Based Integrated Systems for the Prediction of
Drug-Induced Liver Injury (MIP-DILI)12 and Kinetics for Drug Dis-
covery (K4DD)13 Innovative Medicine Initiatives (IMI) with labeled
compounds and has collaborated with multiple PET centers on the
development of PET tracers and synthetic methodology.14,15
IC serves as a center of excellence within the company for iso-
topic labeling and helps to advise on the use of radioactivity in
studies. In a recent unfortunate example, a project wanted to run
a receptor binding study and had contacted a supplier to prepare
the C-14 labeled material. Only after spending $65,000 for the syn-
thesis and having the study fail due to the low speciﬁc activity of
the compound, did they approach IC for advice. IC rapidly labeled
the compound with tritium and the study produced the expected
results. It is important to note that this failure was not due to
the CRO, but rather due to the inexperience of the project with
radioactivity. The CRO provided exactly what was ordered, but
the request was inappropriate for the aims of the study.
There is a perception that the use of radioactivity is outdated
and that IC is a fading ﬁeld. There is no question that IC, as well
as the entire drug industry in general, has undergone a major shift
over the past two decades, including signiﬁcant staff reductions.16
As mass spectrometry (MS) detection limits have improved and the
data handling software has become more robust and capable,
many studies that once used radioactivity have shifted to the use
of MS, including binding studies and imaging.17 This shift will
likely continue; however, signiﬁcant development will need to be
made to obviate the usefulness of radioactivity to the drug devel-
opment process. Quantization of radioactivity is independent of
the molecular environment, unlike MS, which makes it a good tool
when accurate quantitative measurements of unknown materials
is required. For studies such as QWBA and covalent binding assays,
which look at least in part for covalently modiﬁed peptides, radio-
activity remains the best tool.18 It is critical for compound
advancement that a project use the most appropriate analytical
tool, be that MS, radioactivity, ﬂuorescence, or other techniques.
The key is that the data are delivered on time to make decisions
at an acceptable cost.
Given that isotope chemistry is a developed ﬁeld that requires
specialized facilities and workforce, and that a number of contract
laboratories exist that deliver isotopically labeled compounds,
externalization of some or all aspects should be considered. Fur-
thermore, the use of high levels of radioactivity and subsequent
radioactive waste generation imposes an additional level of
bureaucracy and governance that can be partially avoided by using
a CRO. However, externalization imposes a number of additional
costs as the delivery times for externalized compounds are often
longer and there is invariably a loss of project interactions and
input from the isotope chemistry team. Furthermore, the need to
control and conﬁrm the quality and attributes of the compounds
delivered by the CRO and the requirement to manage the inventory
and conduct repuriﬁcations of stored materials, dictates that it is
necessary to maintain a radiochemical laboratory and some staff
(or to pay a CRO to do so on the company’s behalf).
A proper balance must be maintained between ensuring that
projects have adequate and timely support while at the same time
controlling costs as much as possible. Different companies have
addressed the externalization of isotope chemistry in different
ways which varies from a fully externalized model with only anoutsourcing manager to an entirely internally supported model.
This decision generally reﬂects the company’s overall strategic
use of radioactivity: which studies are run using radiolabeled
materials and when they are run. Ideally, even in a fully outsourced
model, a radiochemist would be retained to provide initial input
into the synthetic approach and to evaluate the CRO supplied ana-
lytical data for quality.
At AstraZeneca, we recently undertook a ﬁnancial investigation
to determine the overall cost for synthesizing labeled compounds
internally. It was assumed that internal syntheses would be more
costly than external syntheses, but the degree of the cost differen-
tial was unknown. This analysis included renumeration; raw mate-
rials and consumables; outsourcing of ﬁnal compounds and
intermediates; and facility costs such as depreciation of the build-
ing and equipment, but it did not include construction of the lab-
oratory. By far the most signiﬁcant contributors to the costs were
outsourcing and labor. The results of the analysis showed that
the actual cost of the synthesis of C-14 and H-3 labeled compounds
from internal and external sources was comparable. The cost of SIL
synthesis was lower for external sources while the cost of prepar-
ing radioactive compounds for administration to humans was sub-
stantially less expensive when conducted internally. The costs of
radiolabeled compounds could be reduced somewhat by using a
discount provider, but often these providers are less reliable in
their delivery times and compound quality.
As a result of the ﬁnancial analysis and experiences, AZ IC oper-
ates a hybrid internal–external model. Those compounds which
can be forecast well in advance are placed with CROs for synthesis.
This work stream also overlaps well with the lower cost work
streams as the demand for SIL compounds can typically be forecast
more than 3 months in advance. Some tritium and C-14 work can
also be forecast and can be externalized to help ameliorate the
internal work load. Compounds for which the timing of the deliv-
ery is critical, typically compounds in support of drug discovery,
are synthesized internally. While hADME studies can be forecast
well in advance, they are supported primarily from internal
resources due to the higher cost of externalization.
The synthesis of SIL compounds closely mirrors the synthesis of
medicinal chemistry compounds with the exception of the key
starting materials. Therefore, the syntheses of SIL compounds can
be placed with the same CROs typically used by medicinal chemis-
try groups. If some or all of the medicinal chemistry work is placed
with a CRO, the syntheses of SIL compounds for that project can be
facilitated by using the same CRO. The main expense is then labor,
which can be reduced by moving the synthesis to locations where
the labor is less expensive. Although these laboratories are typi-
cally less experienced at preparing SIL compounds, this deﬁcit
can be offset if the CRO is synthesizing the same or a similar mol-
ecule for the project.
Outsourcing the synthesis of SIL compounds has created some
challenges due to limited availability of some SIL reagents and
higher material cost. This is due, in part, to that fact that large
pharmaceutical companies typically have pre-negotiated price
reductions with suppliers of stable isotope labeled materials that
are often not available to CROs. Whilst it is unusual for this price
difference to offset the cost advantage of outsourcing, it can reduce
the ﬁnancial advantage. A further aspect of IC should be considered
prior to outsourcing a synthesis of a SIL compound; IC often uses
this synthesis to optimize the synthetic route and ensure reproduc-
ibility of the proposed chemistry in order to minimize the amount
of radioactive waste produced during a subsequent C-14 synthesis.
This work will be required prior to the C-14 synthesis, even if the
SIL synthesis is outsourced, therefore outsourcing the synthesis
in some cases may not be the most efﬁcient solution. When out-
sourcing a synthesis, a full proposed reaction scheme is provided

















Scheme 3. Revised synthetic route to a H-2 labeled alpha 7 agonist.
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often provided for use in the synthesis and to serve as reference
standards. For example, in the synthesis of [14C]clozapine, we pro-
vided full experimental details for every step of the synthesis and
the compound was rapidly delivered by the CRO (Scheme 1).19 The
same approach was taken for the alpha 7 project; however, a deu-
terium isotope effect in a key deprotonation step resulted in an
alternate compound being made by halogen-metal exchange
instead (Scheme 2).20 In this case, the CRO rapidly devised an alter-
nate route to the labeled compound and delivered the desired
material (Scheme 3). However, experiences are not always as posi-
tive. For example, one CRO provided H-3 labeled material with a
speciﬁc activity only 30% of the target value, even when they were
provided with full methodology. Furthermore, the certiﬁcate of
analysis claimed the target, rather than the actual speciﬁc activity.
A reworked batch of material from the same CRO also failed to
meet the target speciﬁcation, forcing an internal synthesis.
Ideally, the relationship between the IC group and a CRO should
be a partnership rather than strictly contractual. Both parties
should be interested in improving the support for the business
and in improving the skills of the other. In our experience, a strictly
contractual relationship has resulted in the delivery of the wrong
compound in one case and the right compound with wrong speci-
ﬁcations in another. Open communication and a spirit of coopera-
tion are two ways to help build the trust required. CROs will run
into difﬁculties in delivery just as internal groups will and these
problems should be managed in a constructive manner.
The delivery times of the AZ IC group are depicted in Table 1.
These times reﬂect the time required from the request of the pro-
ject for the compound until the compound is ready for delivery to
the customer. Typically, compounds which take longer than the
average delivery time reﬂect a lack of starting material availability
or an intentional delay in an effort to time the delivery to the study.
We have been unable to achieve these delivery times with outsour-
ced syntheses, although provisions such as having dedicated syn-
thetic personal at a CRO, pre-negotiated contracts, and a
streamlined shipping program accelerates this process. AZ has a
small sample set for the deliveries of custom-synthesis radiochem-
icals; however, that small sample indicates that the delivery times
for H-3 and C-14 labeled compounds is approximately 50–100%
longer than for internally supported projects. The key to a success-
ful, rapid delivery is close interaction and early communication


























Scheme 1. Synthesis of C-14 labeled clozapine.routes which are capable of rapid delivery from intermediates that
an isotope chemistry group would typically keep on hand.
In a typical year, AZ IC delivered 38 C-14, 39 H-3 labeled tracers
and 35 SIL compounds, as illustrated in Table 1. The SIL labeled
compounds were split 18:17 for using internal: external resources.
Additionally, 8 unlabeled compounds were delivered (PET precur-
sors and glucuronide metabolites) from CROs and 28 re-puriﬁca-
tions of existing stocks were conducted in house. For the
incorporation of tritium, hydrogen isotope exchange has been the
method of choice due primarily to the speed and ease of the
method (Table 2).21 Where tritium labeling is not appropriate or
possible, early radioactive work has been supported with C-14.
We attempt to use cost effective approaches by starting from
[14C]cyanide or [14C]CO2 rather than expensive advanced interme-
diates that require long lead times (Table 3).
The approach to cGMP syntheses to support hADME studies and
absolute bioavailability studies has evolved to place a greater
emphasis on performing a cGMP-like bond forming step rather
than a more simplistic approach of performing a cGMP repuriﬁca-
tion of existing material.5
The analysis of labeled compounds, whether they come from
internal or external sources, is a critical consideration. At a mini-
mum, the speciﬁc activity and radiochemical purity should be
checked. Depending on the needs of the study, other purity checks
may be run including UV area%, NMR wt %, trace solvents by GC or
NMR, and 3H NMR. For complex analyses, expert help is sought
from pharmaceutical development (GMP-like syntheses) or medic-
inal chemistry. Ideally, the analysis is conducted by someone inde-
pendent from the synthesis to avoid bias. However, given the small
size of most IC groups, it is not typically possible to devote an FTE
to analytical support. The alternative we have followed involves
the chemist obtaining the data and the site leader reviewing it to
make sure the analysis is appropriate.
IC groups can be placed in many different departments includ-
ing DMPK, Medicinal Chemistry or Process Chemistry. None of
these groups is a perfect ﬁt though, since neither the customer
base, breadth of support to the business, nor type of work, is rep-
licated by any of those departments. However, any organization
can work so long as it recognizes the unique aspects of isotope
chemistry and does not attempt to impose its working model or
work streams upon IC. We feel that alignment of IC within DMPK
provides clear accountability to the main customer and access to
greater budgets. In addition, DMPK has a greater understanding
of the need of the work to advance the drug candidate than does
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Table 1
Number of deliveries by work stream including average and median delivery times
Type of work SIL H-3 C-14 Other Puriﬁcation
Internal or external delivery Internal External Internal Internal External Internal
Number of syntheses 18 17 39 38 8 28
% w/i 3 mon 80 75 100 89 88 100
% w/i 1 mon 25 10 94 52 12 100
Median (wk) 10 10 3 4 8 1.0
Average (wk) 9.2 11.3 2.6 6.4 8.7 1.6
Table 2
Types of reactions used to incorporate tritium into molecules
Type of reaction % Type
Reduction of CAC multiple bonds22 4
Methylation23 4
Reduction with tritide source24 3
Reduction of a chloride22 1
Reduction of a bromide22 13
Reduction of an iodide25,26 39
Hydrogen isotope exchange21 37
Table 3
Reagents used for C-14 incorporation into drug molecules
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sors and has a natural overlap of skill sets with those of IC.
Most large pharmaceutical companies operate from more than
one major research site which creates a dilemma for the organiza-
tion of IC: should its organization reﬂect the overall organization of
the research organization or should it centralize to take advantage
of having a larger central IC group. The arguments are obvious for
having a central group: shared equipment in a single specialized
laboratory, better workforce ﬂexibility, and only one high activity
radioactivity license is required. However, there are some costs
to centralizing that are often overlooked. A proximal location to
the customer allows the IC group to be more responsive, sensitive,
and proactive to the needs of the customer. Informal conversations
can lead to creative solutions to project problems. For example,
conversations between Process Development and IC resulted in
the use of radiolabeled materials to track the fate of process inter-
mediates and assess the efﬁciency of extractions. This resulted in
unambiguous analysis that facilitated faster and more accurate
optimization of process procedures.
Being sited locally also allows for better planning with Medici-
nal Chemistry with regards to upcoming work and for easier prob-
lem resolution when a synthetic difﬁculty is encountered. Many of
these difﬁculties can be resolved with travel and by having good
working relationships with others within the business, but with
limited resources, those types of relationships can be difﬁcult to
form and maintain. At AZ, we have a two-site model, where the
main group is supported by a satellite group which while making
deliveries, also serves as a local resource to the customer. This
reﬂects our clear commitment to, and recognition of, the value of
face-to-face interactions. A two-site model also affords advantages
of greater ﬂexibility regarding radioactive holdings and waste dis-
posal limits. One key attribute for the group is that regardless ofthe site of synthesis and whether it is internal or external, it should
be seamless from the customer’s standpoint.
The actual membership of the group should be composed of
skilled synthetic chemists owing to the fact that trained radio-
chemists are seldom available for entry level positions. It takes
approximately one to two years to train a skilled synthetic chemist
to perform radiochemistry so there is a lag time before the new
hire is a full contributor. IC groups tend to be composed of a higher
proportion of Ph.D. and MS scientists than is typical for a medicinal
chemistry team due to the cost of reagents and the need to work
independently.
Whilst there remains a constant pressure to reduce cost within
R&D, in part by increased use of CROs, there remains a signiﬁcant
advantage to maintaining an internal IC group from both a knowl-
edge and cost perspective. We feel that IC will continue to be an
integral part of the drug discovery business and create a competi-
tive advantage for the company. Many of the more modern medic-
inal chemistry targets such as peptides, oligonucleotides, and
antibody drug conjugates will challenge IC for the next decade
and will require highly skilled and adaptable radiochemists to
meet that demand.
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